Skip to main content
SpringerLink
Log in

Development and validation of a UPLC–MS/MS assay for the quantification of simotinib in human plasma

  • Note
  • Published:
Analytical and Bioanalytical Chemistry Aims and scope Submit manuscript

Abstract

Simotinib is a novel oral small-molecule tyrosine kinase inhibitor that has demonstrated equal or superior antineoplastic activities to erlotinib in preclinical studies. In support of a clinical pharmacokinetic study, a sensitive and accurate liquid chromatography (LC) method with mass spectrometry detection using multiple reaction monitoring (MRM) in positive ion mode was developed and validated for the quantification of simotinib in human plasma. The sample preparation procedure involved a simple protein precipitation with methanol. Erlotinib was used as the internal standard. The optimal chromatographic behavior was achieved on a Zorbax SB-C8 column (2.1 mm × 100 mm, 3.5 μm) using a mixture of 0.1 % formic acid with 10 mM ammonium formate/methanol (20:80, v/v) as the mobile phase. The total LC analysis time per injection was 4 min with a flow rate of 0.2 mL/min. The recovery was greater than 90 % and no significant matrix effect was observed. The assay was validated over the concentration range of 1–1,000 ng/mL. The intra- and interday precision and accuracy of the quality control samples at low, medium, and high concentration levels showed at most 9.4 % relative standard deviation (RSD) and −7.4 to 7.4 % relative errors (RE). Assay selectivity, freeze/thaw stability, storage stability, and dilution effects were also assessed. The method is now used to support clinical pharmacokinetic studies in patients with non-small cell lung cancer (NSCLC) after oral administration of simotinib.

Simotinib, an innovative small-molecule EGFR TKI, can be quickly quantified in human plasma using UPLC-MS/MS assay

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893–1907

    Article  Google Scholar 

  2. Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61:91–112

    Article  Google Scholar 

  3. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O’Connell M, Shepherd FA, Johnson BE (2001) Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19:1734–1742

    CAS  Google Scholar 

  4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

    Article  CAS  Google Scholar 

  5. Chen X, Liu Y, Roe OD, Qian Y, Guo R, Zhu L, Yin Y, Shu Y (2013) Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS One 8:e59314

    Article  CAS  Google Scholar 

  6. Juhasz E, Kim JH, Klingelschmitt G, Walzer S (2013) Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. Eur J Cancer 49:1205–1215

    Article  CAS  Google Scholar 

  7. Brand TM, Iida M, Wheeler DL (2011) Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 11:777–792

    Article  CAS  Google Scholar 

  8. van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692–706

    Article  Google Scholar 

  9. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958–2970

    CAS  Google Scholar 

  10. Tan F, Shen X, Wang D, Xie G, Zhang X, Ding L, Hu Y, He W, Wang Y (2012) Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 76:177–182

    Article  Google Scholar 

  11. Wang HP, Zhang L, Wang YX, Tan FL, Xia Y, Ren GJ, Hu P, Jiang J, Wang MZ, Xiao Y (2011) Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. Chin Med J (Engl) 124:1933

    CAS  Google Scholar 

  12. Zhao Q, Shentu J, Xu N, Zhou J, Yang G, Yao Y, Tan F, Liu D, Wang Y, Zhou J (2011) Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 73:195–202

    Article  Google Scholar 

  13. Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W, Sun Y (2013) Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 14:953–961

    Article  CAS  Google Scholar 

  14. Masters AR, Sweeney CJ, Jones DR (2007) The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 848:379–383

    Article  CAS  Google Scholar 

  15. Liu D, Jiang J, Hu P, Tan F, Wang Y (2009) Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:3781–3786

    Article  CAS  Google Scholar 

  16. Faivre L, Gomo C, Mir O, Taieb F, Schoemann-Thomas A, Ropert S, Vidal M, Dusser D, Dauphin A, Goldwasser F, Blanchet B (2011) A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 879:2345–2350

    Article  CAS  Google Scholar 

  17. Zhen Y, Thomas-Schoemann A, Sakji L, Boudou-Rouquette P, Dupin N, Mortier L, Vidal M, Goldwasser F, Blanchet B (2013) An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci 928:93–97

    Article  CAS  Google Scholar 

  18. US Department of Health and Human Services, Food and Drug Admin-istration, Center for Drug Evaluation and Research (CDER) (2001) FDA guidance for industry: bioanalytical method validation. CDER, Rockville

Download references

Acknowledgments

This study was sponsored by Jiangsu Simcere Pharmaceutical R&D Co. Ltd (Jiangsu, China). It was partly funded by the Chinese National Science and Technology Major Project for New Drug Innovation (2012ZX09303012, 2012ZX09105-301002 and Beijing Municipal Science and Technology Commission Major Project for New Drug Innovation (Z111102071011001, Z121102009212055).

Conflict of interest

No potential conflict of interest was disclosed.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China

    Ning Li, Xiaohong Han, Ping Du, Yuanyuan Song, Xingsheng Hu, Sheng Yang & Yuankai Shi

Authors
  1. Ning Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaohong Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ping Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuanyuan Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xingsheng Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sheng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuankai Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuankai Shi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, N., Han, X., Du, P. et al. Development and validation of a UPLC–MS/MS assay for the quantification of simotinib in human plasma. Anal Bioanal Chem 406, 1799–1805 (2014). https://doi.org/10.1007/s00216-013-7570-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00216-013-7570-1

Keywords

Search

Navigation